ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) recently released a strong earnings report, and the market responded ...

Second Quarter 2025 Results Key Financial Results Revenue: US$264.6m (up ...

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the First Trust NYSE Arca ...

Acadia Pharma (ACAD) is scheduled to announce Q2 earnings results on Wednesday, August 6th, after market close.

As the U.S. market experiences a mix of record highs and tempered expectations due to recent inflation reports, investors are closely monitoring economic indicators that could influence Federal ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Scott Cenci as Senior Vice President, Chief Information and Data Officer. In this role, Scott will lead Acadia’s digital ...

Explore ACADIA Pharmaceuticals' Q2 2025 earnings highlights, featuring strong revenue growth, DAYBUE expansion, NUPLAZID guidance raise, and robust ...

ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its price objective hoisted by JPMorgan Chase & Co. from $30.00 to $34.00 in a report released on Thursday morning,Benzinga reports. The ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets.

Morgan's Scott Power highlights nine ASX healthcare companies from the 2025 Bioshares Biotech Summit with catalysts over next ...

In addition to J.P. Morgan, ACADIA Pharmaceuticals also received a Buy from Leerink Partners’s Marc Goodman in a report issued on July 11.

Neuren Pharmaceutical's reports boosted sales of the Rett syndrome drug Daybue, but two-thirds of US patients are yet to try it.